PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation
Launched by TEXAS CARDIAC ARRHYTHMIA RESEARCH FOUNDATION · Aug 21, 2012
Trial Information
Current as of July 06, 2025
Unknown status
Keywords
ClinConnect Summary
Background:
The efficiency of catheter ablation in drug-refractory atrial fibrillation (AF) is compromised by high incidence of post-ablation AF recurrences requiring multiple ablation procedures (1). Post-PVAI (pulmonary vein antrum isolation) AF recurrence is mostly due to reconnection of the previously isolated PVs (2). Earlier studies have revealed that elimination of dormant PV conduction revealed by adenosine-provocation ensures better outcome as reconnection mostly happens due to presence of incompletely ablated tissue and identification and complete ablation decrease chance of recu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years
- • 2. Patients presenting with drug-refractory PAF undergoing first ablation
- • 3. Ability to understand and provide signed informed consent
- Exclusion Criteria:
- • 1. Previous catheter ablation or MAZE procedure in left atrium
- • 2. Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc
About Texas Cardiac Arrhythmia Research Foundation
The Texas Cardiac Arrhythmia Research Foundation is a leading clinical trial sponsor dedicated to advancing the understanding and treatment of cardiac arrhythmias. With a focus on innovative research and collaboration, the foundation conducts rigorous clinical studies aimed at improving patient outcomes and enhancing therapeutic strategies. By leveraging cutting-edge technology and a team of experienced professionals, the foundation strives to translate scientific findings into effective clinical practices, ultimately contributing to the broader field of cardiovascular health. Through its commitment to excellence and patient-centered care, the Texas Cardiac Arrhythmia Research Foundation plays a pivotal role in shaping the future of arrhythmia management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Austin, Texas, United States
Patients applied
Trial Officials
Andrea Natale, MD
Principal Investigator
TCAI
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials